Back to today’s briefing

Story perspectives

FDA Approves Journavx: Game-Changing Non-Opioid Painkiller

2/4/2025

41 6

Summary

Story summary

The FDA has greenlit Journavx (suzetrigine), a revolutionary non-opioid painkiller designed for adults suffering from moderate to severe acute pain. Created by Vertex Pharmaceuticals, this innovative medication targets pain signals in the peripheral nervous system, steering clear of opioid addiction. At $15.50 per pill, Journavx emerges as a beacon of hope in the ongoing battle against the opioid crisis.

1 of 1

Story summary

The FDA has greenlit Journavx (suzetrigine), a revolutionary non-opioid painkiller designed for adults suffering from moderate to severe acute pain. Created by Vertex Pharmaceuticals, this innovative medication targets pain signals in the peripheral nervous system, steering clear of opioid addiction. At $15.50 per pill, Journavx emerges as a beacon of hope in the ongoing battle against the opioid crisis.